Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
16 Apr 24
8-K
3 Agenda ▪ Business Update ▪ Our Research Strategy ▪ Our Platform ▪ Lead Candidates ▪ Forward Looking ▪ Closing Remarks ▪ Q&A
9 Apr 24
424B3
Prospectus supplement
15 Mar 24
424B3
Prospectus supplement
15 Mar 24
EFFECT
Notice of effectiveness
15 Mar 24
EFFECT
Notice of effectiveness
15 Mar 24
EFFECT
Notice of effectiveness
15 Mar 24
POS AM
Prospectus update (post-effective amendment)
13 Mar 24
POS AM
Prospectus update (post-effective amendment)
13 Mar 24
POS AM
Prospectus update (post-effective amendment)
13 Mar 24
ARS
2023 FY
Annual report to shareholders
13 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
13 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
Departure of Directors or Certain Officers
29 Feb 24
8-K
Entry into a Material Definitive Agreement
24 Jan 24
8-K
Entry into a Material Definitive Agreement
19 Jan 24
8-K
Other Events
4 Jan 24
8-K
ADC Therapeutics Provides Business Updates
4 Jan 24
6-K
Current report (foreign)
19 Dec 23
S-8
Registration of securities for employees
18 Dec 23
S-8
Registration of securities for employees
4 Dec 23
6-K
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
7 Nov 23
6-K
Condensed Consolidated Interim Statement of Operations
7 Nov 23
6-K
Current report (foreign)
11 Sep 23
6-K
Current report (foreign)
30 Aug 23
6-K
Condensed Consolidated Interim Statement of Operations
8 Aug 23
6-K
Current report (foreign)
20 Jul 23
6-K
Current report (foreign)
11 Jul 23
6-K
Current report (foreign)
14 Jun 23
6-K
Condensed Consolidated Interim Statement of Operations
9 May 23
6-K
Invitation to the Annual General Meeting
5 May 23
SC TO-I/A
Issuer tender offer statement (amended)
5 Apr 23
SC TO-I/A
Issuer tender offer statement (amended)
30 Mar 23
SC TO-I/A
Issuer tender offer statement (amended)
29 Mar 23
EFFECT
Notice of effectiveness
27 Mar 23
EFFECT
Notice of effectiveness
21 Mar 23
CORRESP
Correspondence with SEC
21 Mar 23
Latest ownership filings
SC 13G
Oaktree Capital Group Holdings GP, LLC
3 May 24
SC 13D/A
AUVEN THERAPEUTICS HOLDINGS LP
25 Apr 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
Prosight Management, LP
13 Feb 24
SC 13G/A
ASTRAZENECA PLC
12 Feb 24
4
Jeremy Green
9 Feb 24
3
Jeremy Green
9 Feb 24
3
Viviane Monges
2 Jan 24
3
Jose Carmona
2 Jan 24
3
PETER J GRAHAM
2 Jan 24
3
JEAN-PIERRE BIZZARI
2 Jan 24
3
Robert Azelby
2 Jan 24
3
Mohamed Zaki
2 Jan 24
3
Peter Hug
2 Jan 24
3
Ron Squarer
2 Jan 24
3
Victor Sandor
2 Jan 24
3
Thomas Pfisterer
2 Jan 24
3
AMEET MALLIK
2 Jan 24
3
Lisa Michelle Kallebo
2 Jan 24
3
Tyrell Rivers
2 Jan 24
SC 13D/A
AUVEN THERAPEUTICS HOLDINGS LP
28 Apr 23
SC 13G
Prosight Management, LP
17 Apr 23
SC 13G/A
FMR LLC
10 Apr 23
SC 13G/A
Redmile Group, LLC
10 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13D/A
AUVEN THERAPEUTICS HOLDINGS LP
6 Feb 23
SC 13D/A
AUVEN THERAPEUTICS HOLDINGS LP
22 Dec 22
SC 13D/A
AUVEN THERAPEUTICS HOLDINGS LP
9 Dec 22
SC 13D/A
AUVEN THERAPEUTICS HOLDINGS LP
8 Dec 22
SC 13G/A
Redmile Group, LLC
14 Feb 22
SC 13G/A
FMR LLC
9 Feb 22
SC 13G/A
FMR LLC
12 Apr 21
SC 13G
Redmile Group, LLC
16 Feb 21
SC 13G
ASTRAZENECA PLC
10 Feb 21
SC 13G/A
FMR LLC
8 Feb 21
SC 13G
FMR LLC
10 Dec 20
SC 13D/A
AUVEN THERAPEUTICS HOLDINGS LP
13 Oct 20
SC 13D
HPWH TH AG
14 Sep 20
SC 13D
AUVEN THERAPEUTICS HOLDINGS LP
29 May 20